Loading
companiesCompany
Pheon Therapeutics
Pheon Therapeutics, of London, designs antibody-drug conjugates against an undisclosed target overexpressed across a wide range of solid tumours; its lead carries eight topoisomerase 1 inhibitor molecules per antibody and showed a wide therapeutic index preclinically. It raised a 120 million dollar Series B in 2024 and has entered early human trials.
Overview
Pheon Therapeutics is a London-based antibody-drug conjugate specialist building a pipeline of ADCs against undisclosed new targets and clinically validated ones, using either its proprietary payload platform, which acts through a mechanism distinct from established payloads, or established linker-payloads. Its first three assets address an undisclosed novel target that is highly overexpressed across a wide range of solid tumours; the lead uses a DAR8 topoisomerase 1 inhibitor linker-payload and the company reported an unusually wide preclinical therapeutic index, with a first phase 1 trial planned from 2024. By September 2025 the company described itself as clinical-stage. In May 2024 Pheon closed a USD 120 million Series B led by TCGX with BVF Partners, Lightspeed and Perceptive Advisors alongside existing investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.
Headquarters
London, GB
Funding
All startupsStartup
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B | 2024 | $120M | pheontx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- Lead target undisclosed. Series A (2022) not fetched and omitted.
Similar pages
- CompanyMariana Oncology
Shares Forbion, Atlas Venture.
- CompanyMythic Therapeutics
- CompanyObsidian Therapeutics
Shares TCGX (TCG Crossover), Atlas Venture.
- CompanyTriana Biomedicines
Shares Lightspeed Venture Partners, Atlas Venture.
- CompanyEnlaza Therapeutics
Shares Lightspeed Venture Partners, Antibody-drug conjugate (ADC).
- CompanyAdcendo